Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect and DDI Study of Daridorexant
NCT03017495Phase 1Completed
- Sponsor
- Idorsia
- Start
- Jan 2017
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of daridorexant in Insomnia, sponsored by Idorsia. Primary endpoints: Maximum plasma concentration of ACT-541468 at Day 8, Time to reach Cmax of ACT-541468 at Day 8 and 10 more. Started Jan 2017; status: completed.
02
Drugs
daridorexant
03
Conditions
Insomnia
Beyond the preview
Go deeper on NCT03017495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03017495.